Patents by Inventor Philip Erna H. Heyns

Philip Erna H. Heyns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ERDAFITINIB FORMULATIONS AND OSMOTIC SYSTEMS FOR INTRAVESICAL ADMINISTRATION
    Publication number: 20250041574
    Abstract: Provided herein are solid pharmaceutical compositions comprising an L-lactate salt of erdafitinib, processes for making such formulations, and drug delivery systems comprising such formulations, including systems for intravesical administration.
    Type: Application
    Filed: August 15, 2024
    Publication date: February 6, 2025
    Inventors: Karen DANIEL, Jens Julien Maurits André DHONDT, Kristof Johan W DUBOIS, Philip Erna H HEYNS, Kristof Leonard KIMPE, Srinivas MAMIDI, Dennis GIESING
  • ERDAFITINIB FORMULATIONS AND SYSTEMS FOR INTRAVESICAL ADMINISTRATION
    Publication number: 20240350485
    Abstract: Provided herein are solid pharmaceutical compositions comprising erdafitinib, processes for making such formulations, and drug delivery systems comprising such formulations, including systems for intravesical administration.
    Type: Application
    Filed: October 12, 2022
    Publication date: October 24, 2024
    Inventors: Srinivas MAMIDI, Karen DANIEL, Dennis GIESING, Philip Erna H HEYNS, Jens Julien Maurits André DHONDT, Urbain Alfons C DELAET
  • DARUNAVIR COMBINATION FORMULATIONS
    Publication number: 20230302024
    Abstract: This invention relates to solid oral dosage forms of the HIV inhibitor Darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof.
    Type: Application
    Filed: May 5, 2023
    Publication date: September 28, 2023
    Inventors: Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Eugeen Maria Jozef JANS, Roel Jos M. MERTENS, Geert VAN DER AVOORT
  • OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS
    Publication number: 20230293493
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6 -dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy -benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Application
    Filed: May 26, 2023
    Publication date: September 21, 2023
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB
    Publication number: 20230226081
    Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
    Type: Application
    Filed: May 7, 2021
    Publication date: July 20, 2023
    Inventors: Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
  • TREATMENTS OF PROSTATE CANCER WITH COMBINATIONS OF ABIRATERONE ACETATE AND NIRAPARIB
    Publication number: 20230226080
    Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
    Type: Application
    Filed: May 7, 2021
    Publication date: July 20, 2023
    Inventors: Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
  • TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB
    Publication number: 20230218640
    Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
    Type: Application
    Filed: May 7, 2021
    Publication date: July 13, 2023
    Inventors: Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
  • Darunavir combination formulations
    Patent number: 11654150
    Abstract: This invention relate to solid oral dosage forms of tire HIV inhibitor Darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulation thereof.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: May 23, 2023
    Assignee: Janssen Sciences Ireland UC
    Inventors: Urbain Alfons C. Delaet, Philip Erna H. Heyns, Eugeen Maria Jozef Jans, Roel Jos M. Mertens, Geert Van Der Avoort
  • Opioid receptor modulator dosage formulations
    Patent number: 11484527
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: November 1, 2022
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Opioid receptor modulator dosage formulations
    Patent number: 11311516
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: April 26, 2022
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS
    Publication number: 20220096440
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Application
    Filed: December 8, 2021
    Publication date: March 31, 2022
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS
    Publication number: 20220040151
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Application
    Filed: October 21, 2021
    Publication date: February 10, 2022
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Opioid receptor modulator dosage formulations
    Patent number: 11229627
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: January 25, 2022
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS
    Publication number: 20220016034
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Application
    Filed: July 17, 2020
    Publication date: January 20, 2022
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Opioid receptor modulator dosage formulations
    Patent number: 11160792
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: November 2, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Opioid receptor modulator dosage formulations
    Patent number: 11090291
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: August 17, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • DARUNAVIR FORMULATIONS
    Publication number: 20210244749
    Abstract: This invention relates to solid oral dosage forms of the HIV inhibitor darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof.
    Type: Application
    Filed: April 27, 2021
    Publication date: August 12, 2021
    Inventors: Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Eugeen Maria Jozef JANS
  • OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS
    Publication number: 20210205268
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino }-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Application
    Filed: February 12, 2021
    Publication date: July 8, 2021
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Opioid receptor modulator dosage formulations
    Patent number: 11007179
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: May 18, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS
    Publication number: 20210030720
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Application
    Filed: October 8, 2020
    Publication date: February 4, 2021
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns